Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $49.57 Consensus PT from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has earned an average recommendation of “Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages […]
More Stories
US Stocks Soar, Oil Prices Plunge as Market Fears of Israel–Iran Conflict Spreading Fade: Analyst
By Andrew Moran U.S. stocks surged at the start of the trading week, rebounding from Friday’s selloff sparked by geopolitical...
German Police Shut Down Darknet Marketplace Selling Drugs
By Chris Summers One of the world’s biggest darknet marketplaces for fentanyl and other drugs, Archetyp, has been taken down...
South Africa’s Emotional WTC Triumph: Proteas Win First Major Cricket Trophy in 27 Years
By The Associated Press LONDON—South Africa on Saturday claimed its first major cricket trophy in 27 years when it wrapped...
Trump Says US-UK Trade Deal ‘Signed and Done’ at G7 Summit
By Emel Akan CALGARY, Canada—President Donald Trump announced on Monday that the recently finalized UK-US bilateral trade agreement is “signed...
Former New York Assembly Candidate Charged With Campaign Finance Fraud
By Frank Fang A Chinese national allegedly stole around $162,000 in taxpayer money to fund his 2024 campaign for New...
7 Best Delivery Apps to Make Money in 2025
In the current fast-paced world, side hustles have become an increasingly popular means of earning extra cash, specifically, food delivery...